MA33181B1 - Dérivés de pyrrolo [2,3-b]pyridine pour l'inhibition des kinases raf - Google Patents

Dérivés de pyrrolo [2,3-b]pyridine pour l'inhibition des kinases raf

Info

Publication number
MA33181B1
MA33181B1 MA34228A MA34228A MA33181B1 MA 33181 B1 MA33181 B1 MA 33181B1 MA 34228 A MA34228 A MA 34228A MA 34228 A MA34228 A MA 34228A MA 33181 B1 MA33181 B1 MA 33181B1
Authority
MA
Morocco
Prior art keywords
pyrrolo
pyridine
difluoro
carbonyl
phenyl
Prior art date
Application number
MA34228A
Other languages
Arabic (ar)
English (en)
Inventor
Prabha N Ibrahim
Wayne Spevak
Hanna Cho
Hongyao Zhu
Original Assignee
Plexxikon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plexxikon Inc filed Critical Plexxikon Inc
Publication of MA33181B1 publication Critical patent/MA33181B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

L'INVENTION CONCERNE LE PROPANE-1-ACIDE SULFONIQUE {2,4-DIFLUORO-3-[5-(2-MÉTHOXY-PYRIMIDINE-5-YL)-1H-PYRROLO[2,3-B]PYRIDINE-3-CARBONYL]-PHÉNYL}-AMIDE, LE PROPANE-1-ACIDE SULFONIQUE [3-(5-CYANO-1H-PYRROLO[2,3-B]PYRIDINE-3-CARBONYL)-2,4-DIFLUORO-PHÉNYL]-AMIDE,LE PROPANE-1-ACIDE SULFONIQUE [3-(5-CYANO-1H-PYRROLO[2,3-B]PYRIDINE-3-CARBONYL)-2-FLUORO-PHÉNYL]-AMIDE, LE N-[3-(5-CYANO-1H-PYRROLO[2,3-B] PYRIDINE-3-CARBONYL)-2,4-DIFLUORO-PHÉNYL]-2,5-DIFLUORO-BENZÈNESULFONAMIDE,LE N-[3-(5-CYANO-1H-PYRROLO[2,3-B] PYRIDINE-3-CARBONYL)-2,4-DIFLUORO-PHÉNYL]-3-FLUORO-BENZÈNESULFONAMIDE, LE PYRROLIDINE-1-ACIDE SULFONIQUE [3-(5-CYANO-1H-PYRROLO[2,3-B] PYRIDINE-3-CARBONYL)-2,4-DIFLUORO-PHÉNYL]-AMIDE, LE N,N-DIMÉTHYLAMINO-ACIDE SULFONIQUE [3-(5-CYANO-1H-PYRROLO[2,3-B]PYRIDINE-3-CARBONYL)-2,4-DIFLUORO-PHÉNYL]-AMIDE, ET LEURS SELS, LEURS FORMULATIONS, LEURS CONJUGUÉS, LEURS DÉRIVÉS, LEURS FORMES ET LEURS UTILISATIONS. DANS CERTAINS ASPECTS ET MODES DE RÉALISATION, LES COMPOSÉS SELON L'INVENTION OU LEURS SELS, LEURS FORMULATIONS, LEURS CONJUGUÉS, LEURS DÉRIVÉS, ET LEURS FORMES SONT ACTIFS SUR AU MOINS UNE PROTÉINE KINASE RAF. L'INVENTION CONCERNE ÉGALEMENT LEURS PROCÉDÉS D'UTILISATION POUR TRAITER DES MALADIES ET DES ÉTATS, Y COMPRIS DES MALADIES ET ÉTATS ASSOCIÉS À L'ACTIVITÉ DES PROTÉINES KINASES RAF, NOTAMMENT LE MÉLANOME, LE GLIOME, LE CANCER COLORECTAL, LE CANCER DE LA THYROÏDE, LE CANCER DU POUMON, LE CANCER DE L'OVAIRE, LE CANCER DE LA PROSTATE, ET LE CANCER DU TRACTUS BILIAIRE.
MA34228A 2009-03-11 2010-03-10 Dérivés de pyrrolo [2,3-b]pyridine pour l'inhibition des kinases raf MA33181B1 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US15940209P 2009-03-11 2009-03-11
US15939509P 2009-03-11 2009-03-11
US15939009P 2009-03-11 2009-03-11
US15940009P 2009-03-11 2009-03-11
US15939209P 2009-03-11 2009-03-11
US15939609P 2009-03-11 2009-03-11
US15940609P 2009-03-11 2009-03-11
PCT/US2010/026816 WO2010104945A1 (fr) 2009-03-11 2010-03-10 Dérivés de pyrrolo [2, 3-b] pyridine pour l'inhibition des kinases raf

Publications (1)

Publication Number Publication Date
MA33181B1 true MA33181B1 (fr) 2012-04-02

Family

ID=42199540

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34228A MA33181B1 (fr) 2009-03-11 2010-03-10 Dérivés de pyrrolo [2,3-b]pyridine pour l'inhibition des kinases raf

Country Status (23)

Country Link
US (1) US8901301B2 (fr)
EP (1) EP2406259A1 (fr)
JP (1) JP2012520307A (fr)
KR (1) KR101663339B1 (fr)
CN (1) CN102421776A (fr)
AR (1) AR075812A1 (fr)
AU (1) AU2010224245B2 (fr)
BR (1) BRPI1011515A2 (fr)
CA (1) CA2755045A1 (fr)
CO (1) CO6620074A2 (fr)
CR (1) CR20110476A (fr)
EC (1) ECSP11011313A (fr)
MA (1) MA33181B1 (fr)
MX (1) MX2011009489A (fr)
MY (1) MY161861A (fr)
NI (1) NI201100168A (fr)
NO (1) NO20111241A1 (fr)
PE (1) PE20120184A1 (fr)
RU (1) RU2011141123A (fr)
SG (2) SG174257A1 (fr)
TW (1) TW201036973A (fr)
WO (1) WO2010104945A1 (fr)
ZA (1) ZA201106599B (fr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063888A2 (fr) 2006-11-22 2008-05-29 Plexxikon, Inc. Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
US8158636B2 (en) 2008-05-19 2012-04-17 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
EP2356116A1 (fr) 2008-11-20 2011-08-17 OSI Pharmaceuticals, Inc. Pyrroloý2,3-b¨-pyridines et pyrroloý2,3-b¨-pyrazines substituées
CA2738573C (fr) 2009-04-03 2013-02-19 F. Hoffmann-La Roche Ag Compositions et utilisations associees
JP2013510166A (ja) 2009-11-06 2013-03-21 プレキシコン インコーポレーテッド キナーゼ調節のための化合物、方法およびその適用
EP2501236B1 (fr) 2009-11-18 2017-03-29 Plexxikon Inc. Dérivés de la benzènesulfonamide de N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phényl]-4- en tant que modulateurs de la kinase du protein Raf pour le traitement du cancer
CA2784393A1 (fr) 2009-12-23 2011-06-30 Plexxikon, Inc. Composes et methodes pour la modulation des kinases, et leurs indications
TWI510487B (zh) 2010-04-21 2015-12-01 Plexxikon Inc 用於激酶調節的化合物和方法及其適應症
US20130072495A1 (en) 2010-05-14 2013-03-21 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
WO2012075327A1 (fr) 2010-12-02 2012-06-07 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Méthodes de traitement d'une tumeur au moyen d'un anticorps qui se lie spécifiquement à grp94
PE20141360A1 (es) * 2011-02-07 2014-10-13 Plexxikon Inc Compuestos y metodos para la modulacion de quinasas e indicaciones para los mismos.
WO2012149547A1 (fr) * 2011-04-28 2012-11-01 Duke University Procédés de traitement d'hémoglobinopathies
CA2836474A1 (fr) 2011-05-17 2012-11-22 Plexxikon Inc. Modulation de kinase et indications pour celle-ci
US9988687B2 (en) * 2011-09-20 2018-06-05 The George Washington Univeristy Companion diagnostics for cancer and screening methods to identify companion diagnostics for cancer based on splicing variants
US9249110B2 (en) 2011-09-21 2016-02-02 Neupharma, Inc. Substituted quinoxalines as B-raf kinase inhibitors
US20130172375A1 (en) * 2011-12-13 2013-07-04 Hoffmann-La Roche Inc. Pharmaceutical composition
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
US9150570B2 (en) * 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
US20150182490A1 (en) 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
TWI601725B (zh) 2012-08-27 2017-10-11 加拓科學公司 取代的氮雜吲哚化合物及其鹽、組合物和用途
JP6318156B2 (ja) 2012-09-06 2018-04-25 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼをモジュレートするための化合物および方法、ならびにその指標
US9861685B2 (en) 2012-11-20 2018-01-09 Duke University Methods of treating hemoglobinopathies
ME03000B (fr) 2012-12-21 2018-10-20 Plexxikon Inc Composés et procédés pour la modulation de kinase, et indications associées
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
CN105073747B (zh) 2013-03-15 2017-06-06 普莱希科公司 杂环化合物及其应用
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
RU2015149937A (ru) 2013-05-30 2017-07-06 Плексксикон Инк. Соединения для модулирования киназы и показания к их применению
WO2015108907A2 (fr) 2014-01-14 2015-07-23 Dana-Farber Cancer Institute, Inc. Compositions et méthodes pour l'identification, l'évaluation, la prévention, et le traitement d'un mélanome à l'aide d'isoformes de pd-l1
US9771369B2 (en) 2014-03-04 2017-09-26 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
ES2774177T3 (es) 2014-09-15 2020-07-17 Plexxikon Inc Compuestos heterocíclicos y usos de estos
US20170248603A1 (en) 2014-10-06 2017-08-31 Dana-Farber Cancer Institute, Inc. Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response
US10160755B2 (en) 2015-04-08 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN112574196A (zh) 2015-05-06 2021-03-30 普莱希科公司 调节激酶的1H-吡咯并[2,3-b]吡啶衍生物的合成
SMT202000535T1 (it) 2015-05-06 2020-11-10 Plexxikon Inc Forme solide di composto modulante chinasi
US10829484B2 (en) 2015-07-28 2020-11-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
HK1255102A1 (zh) 2015-09-21 2019-08-02 Plexxikon Inc. 杂环化合物及其应用
US9938273B2 (en) 2015-12-07 2018-04-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US10160747B2 (en) 2016-03-16 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
TW201815766A (zh) 2016-09-22 2018-05-01 美商普雷辛肯公司 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症
JP7193460B2 (ja) 2016-12-23 2022-12-20 プレキシコン インコーポレーテッド Ｃｄｋ８調節およびその適応症のための化合物および方法
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2018175311A1 (fr) 2017-03-20 2018-09-27 Plexxikon Inc. Formes cristallines de l'acide 4-(1-(1,1-di(pyridin-2-yl)éthyl)-6-(3,5-diméthylisoxazol-4-yl)-1h- pyrrolo[3,2-b]pyridin-3-yl)benzoïque inhibiteur de bromodomaine
WO2018226846A1 (fr) 2017-06-07 2018-12-13 Plexxikon Inc. Composés et procédés de modulation de kinase
BR112019028235B1 (pt) 2017-07-25 2024-04-30 Plexxikon, Inc. Composições e seus métodos de preparação
US10717735B2 (en) 2017-10-13 2020-07-21 Plexxikon Inc. Solid forms of a compound for modulating kinases
CA3080197C (fr) 2017-10-27 2023-12-19 Plexxikon Inc. Formulation d'un compose modulant les kinases
AU2019216264B2 (en) 2018-01-31 2023-08-31 Heparegenix Gmbh Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
US11149011B2 (en) 2018-03-20 2021-10-19 Plexxikon Inc. Compounds and methods for IDO and TDO modulation, and indications therefor
GB201809460D0 (en) * 2018-06-08 2018-07-25 Crt Pioneer Fund Lp Salt form
WO2019243315A1 (fr) 2018-06-21 2019-12-26 Heparegenix Gmbh Inhibiteurs de protéine kinase tricycliques pour favoriser la régénération du foie ou réduire ou prévenir la mort des hépatocytes
SG11202012732UA (en) 2018-07-16 2021-02-25 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
JP7636646B2 (ja) 2019-04-09 2025-02-27 オプナ バイオ ソシエテ アノニム Ｅｐ３００またはｃｂｐの調節のための縮合アジンおよびその適応
JP7629442B2 (ja) 2019-07-29 2025-02-13 ヘパリジェニックス ゲーエムベーハー 肝臓再生を促進または肝細胞死を縮減もしくは防止するためのヘテロアリール置換ピラゾロ－ピリジンタンパク質キナーゼ阻害剤
WO2021113625A1 (fr) 2019-12-06 2021-06-10 Plexxikon Inc. Composés et procédés de modulation de cd73 et leurs indications
CA3164361A1 (fr) 2020-01-15 2021-07-22 Heparegenix Gmbh Derives de 3-benzoyl-1h-pyrrolo[2,3-b]pyridine utilises en tant qu'inhibiteurs de mkk4 pour le traitement de maladies du foie
JP7842698B2 (ja) 2020-04-23 2026-04-08 オプナ バイオ ソシエテ アノニム Ｃｄ７３調節のための化合物及び方法並びにそれらの表示
AU2021263383A1 (en) 2020-04-29 2022-11-24 Plexxikon Inc. Synthesis of heterocyclic compounds
WO2021255212A1 (fr) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Agents de dégradation de braf
AU2021327375A1 (en) 2020-08-21 2023-03-16 Opna Bio SA Combinational drug anticancer therapies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140070676A (ko) 2002-09-06 2014-06-10 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
MY153898A (en) * 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
PE20121126A1 (es) * 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa

Also Published As

Publication number Publication date
PE20120184A1 (es) 2012-03-28
BRPI1011515A2 (pt) 2016-03-29
CO6620074A2 (es) 2013-02-15
CR20110476A (es) 2012-01-04
KR20110125670A (ko) 2011-11-21
WO2010104945A1 (fr) 2010-09-16
AR075812A1 (es) 2011-04-27
US8901301B2 (en) 2014-12-02
NI201100168A (es) 2012-01-11
TW201036973A (en) 2010-10-16
US20100286178A1 (en) 2010-11-11
NO20111241A1 (no) 2011-09-28
KR101663339B1 (ko) 2016-10-06
AU2010224245B2 (en) 2016-07-21
ECSP11011313A (es) 2011-10-31
MX2011009489A (es) 2011-10-11
RU2011141123A (ru) 2013-04-20
JP2012520307A (ja) 2012-09-06
SG174257A1 (en) 2011-10-28
CA2755045A1 (fr) 2010-09-16
ZA201106599B (en) 2014-02-26
AU2010224245A1 (en) 2011-09-29
CN102421776A (zh) 2012-04-18
EP2406259A1 (fr) 2012-01-18
SG10201402977WA (en) 2014-09-26
MY161861A (en) 2017-05-15

Similar Documents

Publication Publication Date Title
MY161861A (en) Pyrrolo [2,3-] pyridine kinase inhibitors
DK1780197T3 (da) 5-Substituerede 2-phenylamino-benzamider som MEK-inhibitorer
WO2007120883A3 (fr) Compositions et leurs utilisations sur l'hepcidine
NO20091509L (no) Substituerte tetrahydropyrrolopyrazinforbindelser med affinitet KCNQ2/3 K+ kanal og anvendelse derav i medikamenter
PA8637601A1 (es) Compuestos moduladores de la actividad de c-kit y usos de los mismos
EA200801551A1 (ru) Применение сульфонамидных производных в лечении расстройств метаболизма и нервной системы
NO20071843L (no) Substituerte anilinderivater
WO2006012642A3 (fr) Derives de pyrrole en tant qu'agents pharmaceutiques
NO20074431L (no) Pyrrolopyrimidiner nyttige som proteinkinaseinhibitorer
NO20076659L (no) Pyrrolo(2,3-B)pyridinderivater som protein kinase inhibitorer
MA30291B1 (fr) Derives de l'azolopyridin-3-one en tant qu'inhibiteurs de la lipase endotheliale
EA200300793A1 (ru) Производные 3-(4-амидопиррол-2-илметилиден)-2-индолинона в качестве ингибиторов протеинкиназ
WO2004056827A3 (fr) Derives de pyrrolo-pyrazoles substitues constituant des inhibiteurs de kinases
EA200602062A1 (ru) Амидосоединения и их применение в качестве фармацевтических средств
EA201290255A1 (ru) Способы и композиции для лечения рака
MA28279A1 (fr) Derives d'indole et utilisation de ceux-ci comme inhibiteurs de kinase, notamment des inhibiteurs de ikk2
EP2123649A4 (fr) Dérivés de 3-pyrrolo-cyclohexylène-2-dihydro-indolinone et utilisations de ceux-ci
NO20071438L (no) 4-arylspirosykloalky 1-2-aminopyrimidinkarboksamid KCNQ kaliumkanal modulerende forbindelser
MA28370A1 (fr) Derives de alkylpiperazine-et alkylhomopiperazine-carboxylates, leur preparation et leur application en tant qu'inhibiteurs de l'enzyme faah
WO2006047032A3 (fr) Composes indole convenant comme agents selectifs par rapport a la serotonine
ATE478876T1 (de) Thienopyridine als allosterische verstärker des m4-muscarinrezeptors
MA28366A1 (fr) Derives de piperidinylalkylcarbamates, leur preparation et leur application comme inhibiteurs de l'enzyme faah
EP2076132A4 (fr) Sel de l'acide p-toluène sulfonique de 5-amino-3-(2'-0-acétyl-3'-désoxy-beta -d-ribofuranosyl)-3h-thiazole [4, 5-d]pyrimidine-2-one et ses procédés de préparation
EA200800011A1 (ru) Тиенопиримидиновые и тиенопиридиновые модуляторы киназы
EA200600468A1 (ru) Биполярные транс-каротиноидные соли и их применение